We are live on ! Find out more
TRAW icon

Traws Pharma

28 hedge funds and large institutions have $6.62M invested in Traws Pharma in 2026 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

71% more capital invested

Capital invested by funds: $3.86M → $6.62M (+$2.76M)

27% more funds holding

Funds holding: 2228 (+6)

2.52% more ownership

Funds ownership: 42.78%45.3% (+2.5%)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
28
Holders Change
+6
Holders Change %
+27.27%
% of All Funds
0.34%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
2
Reduced
4
Closed
7
Calls
Puts
Net Calls
Net Calls Change

TRAW Hedge Fund Activity: Q1 2026 in Review

28 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q1 2026, worth a combined $6.62M — up 71% from $3.86M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new TRAW positions and 7 closed out — a net gain of 7 holders — while 2 added to existing stakes and 4 trimmed.

The largest buyer was Dauntless Investment Group, opening a new position worth an estimated $784K. The largest seller was Squadron Capital Management, cutting an estimated $379K.

  • 28 institutional investors held Traws Pharma (TRAW) as of Q1 2026, up from 22 in Q4 2025.
  • Funds reported $6.62M of Traws Pharma stock for Q1 2026, up 71% quarter-over-quarter.
  • 14 funds opened new Traws Pharma positions in Q1 2026 and 7 closed out, a net change of +7 holders.
  • The largest Traws Pharma buyer in Q1 2026 was Dauntless Investment Group, an estimated $784K added.
  • The largest Traws Pharma seller in Q1 2026 was Squadron Capital Management, an estimated $379K sold.

Based on aggregated 13F filings for Q1 2026.